Literature DB >> 7452494

Oxazepam kinetics: effects of age and sex.

D J Greenblatt, M Divoll, J S Harmatz, R I Shader.   

Abstract

Thirty-eight healthy male and female volunteers, 22 to 84 years of age, ingested single 30-mg doses of oxazepam tablets in the fasting state. Oxazepam plasma concentrations were determined by electron-capture gas-liquid chromatography in multiple samples drawn during 48 hr after the dose. Absorption of oxazepam was relatively slow with peak plasma levels reached an average of 2 to 3 hr after dosage. First-order absorption was observed in only 22 of the 38 subjects. Elimination half-life ranged from 4.9 to 19.4 hr and was longer (P < .05) in females (mean: 9.7 hr) than in males (7.8 hr). Half-life was not associated with age in males but tended to increase with age in females (r = 0.45). Oxazepam was extensively bound to plasma protein. The mean free fraction was 4.3% and did not differ between sexes. Free fraction tended to increase with age (r = 0.25), in part because of significantly lower plasma albumin concentrations in the elderly (r = -0.58). Assuming 100% systemic availability, clearance of total as well as unbound oxazepam was significantly greater in men than in women. Intrinsic clearance tended to decline with age in men (r = -0.21) and women (r = -0.24) but these associations were not significant. Higher oxazepam clearance was associated with heavy cigarette smoking but this did not explain the sex-related difference. Thus, sex is a more important determinant of oxazepam clearance than is age.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7452494

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  65 in total

Review 1.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

5.  The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam.

Authors:  Beitske E Smink; Berendina J A Hofman; Albert Dijkhuizen; Klaas J Lusthof; Johan J de Gier; Antoine C G Egberts; Donald R A Uges
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

6.  Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects.

Authors:  J Sonne; S Loft; M Døssing; S Boesgaard; F Andreasen
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

7.  Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium.

Authors:  H R Ochs; E Steinhaus; A Locniskar; M Knüchel; D J Greenblatt
Journal:  Klin Wochenschr       Date:  1982-04-15

Review 8.  Sex-related differences in drug disposition in man.

Authors:  K Wilson
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

9.  Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate.

Authors:  R I Shader; D J Greenblatt; D A Ciraulo; M Divoll; J S Harmatz; A Georgotas
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 10.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.